A High Sensitivity LC/MS/MS Method for Quantitative Determination of Telmisartan in Human Plasma

Introduction

Telmisartan is an angiotensin II receptor antagonist commonly used in the treatment of hypertension and heart failure. Bioanalysis of telmisartan has been reported for human pharmacokinetics and bioequivalence studies, which is carried out mostly on LC/MS/MS with solid phase extraction (SPE) method for high sensitivity and selectivity. The reliability of a bioassay depends on the performance of LC/MS/MS system employed and the method of sample pre-treatment. With rapid progress of interface and triple quadrupole MS techniques, simpler sample pre-treatment without SPE may be adopted to achieve not only reliable quantitative results, but also higher throughput and lower running cost. In this issue of Application News, a high sensitivity LC/MS/MS method for quantitative determination of telmisartan in human plasma is described. The method was developed on LCMS-8050, a tandem mass spectrometer with a heated ESI interface. The high sensitivity and robust interface design of the system allow the use of protein-precipitation only in plasma pre-treatment and achieve a LLOQ of 4 pg/mL in plasma.

November 4, 2015 GMT